Literature DB >> 19123268

Expression of RAC2 in endothelial cells is required for the postnatal neovascular response.

Pradip De1, Qiong Peng, Dmitry O Traktuev, Dmitry O Traktuevc, Weiming Li, Mervin C Yoder, Keith L March, Donald L Durden.   

Abstract

Herein, we describe an obligate role for the hematopoietic specific GTPase, RAC2 in endothelial integrin signaling and the postnatal neovascularization response in vivo. Using a Rac2 knockout mouse model, we discovered that despite the presence of both RAC1 and RAC2 protein in endothelial cells, RAC2 is obligately required for the postnatal neovascular response and alphavbeta3/ alpha4beta1/alpha5beta1 integrin-directed migration on vitronectin, H296 and CH271, fibronectin fragments, respectively. The molecular basis for RAC2 specificity was explored. A genetic analysis of Syk -/+ or Syk-/+;Rac2 -/+ mice revealed that SYK kinase is required for the integrin induced activation of RAC2. The analysis of endothelial cells from Rac2-/+ versus Syk-/+;Rac2-/+ mice provided genetic evidence that SYK-RAC2 signaling axis regulates integrin (alphavbeta3, alpha4beta1 and alpha5beta1) dependent migration. Our results provide evidence that a specific region of the nonreceptor protein tyrosine kinase, SYK, the B linker region containing Y342 and Y346 is required for SYK's regulation of RAC2 and integrin dependent migration. Moreover, the capacity of mice to vascularize the ischemic hindlimb following femoral artery ligation or matrigel plugs was markedly reduced in mice homozygous deficient for the Rac2 gene. These findings identify a novel signaling axis for the induction and potential modulation of postnatal angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19123268      PMCID: PMC2767303          DOI: 10.1016/j.yexcr.2008.10.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  56 in total

Review 1.  What tangled webs they weave: Rho-GTPase control of angiogenesis.

Authors:  B A Bryan; P A D'Amore
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

2.  Structural basis for the requirement of two phosphotyrosine residues in signaling mediated by Syk tyrosine kinase.

Authors:  Teresa D Groesch; Fei Zhou; Sampo Mattila; Robert L Geahlen; Carol Beth Post
Journal:  J Mol Biol       Date:  2005-12-27       Impact factor: 5.469

3.  The Rac effector p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucleotide exchange activity.

Authors:  Wenyu Ming; Shijun Li; Daniel D Billadeau; Lawrence A Quilliam; Mary C Dinauer
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

4.  Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine).

Authors:  Jean-Claude Gevrey; Beth M Isaac; Dianne Cox
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

5.  Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense.

Authors:  A W Roberts; C Kim; L Zhen; J B Lowe; R Kapur; B Petryniak; A Spaetti; J D Pollock; J B Borneo; G B Bradford; S J Atkinson; M C Dinauer; D A Williams
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

Review 6.  Integrins in angiogenesis and lymphangiogenesis.

Authors:  Christie J Avraamides; Barbara Garmy-Susini; Judith A Varner
Journal:  Nat Rev Cancer       Date:  2008-05-22       Impact factor: 60.716

7.  Potential of baboon endothelial progenitor cells for tissue engineered vascular grafts.

Authors:  Monica T Hinds; MinHui Ma; Noi Tran; Ann E Ensley; Stephanie M Kladakis; Keri B Vartanian; Brandon D Markway; Robert M Nerem; Stephen R Hanson
Journal:  J Biomed Mater Res A       Date:  2008-09       Impact factor: 4.396

8.  Syk and Slp-76 mutant mice reveal a cell-autonomous hematopoietic cell contribution to vascular development.

Authors:  Eric Sebzda; Chris Hibbard; Shawn Sweeney; Farhad Abtahian; Natalie Bezman; Gina Clemens; Jonathan S Maltzman; Lan Cheng; Feiyan Liu; Martin Turner; Victor Tybulewicz; Gary A Koretzky; Mark L Kahn
Journal:  Dev Cell       Date:  2006-09       Impact factor: 12.270

9.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.

Authors:  David K Jin; Koji Shido; Hans-Georg Kopp; Isabelle Petit; Sergey V Shmelkov; Lauren M Young; Andrea T Hooper; Hideki Amano; Scott T Avecilla; Beate Heissig; Koichi Hattori; Fan Zhang; Daniel J Hicklin; Yan Wu; Zhenping Zhu; Ashley Dunn; Hassan Salari; Zena Werb; Neil R Hackett; Ronald G Crystal; David Lyden; Shahin Rafii
Journal:  Nat Med       Date:  2006-04-30       Impact factor: 53.440

10.  Integrin signaling is critical for pathological angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Weiyi Feng; David R Phillips; Tatiana V Byzova
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

View more
  14 in total

Review 1.  Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Authors:  Nandini Dey; Pradip De; Leyland-Jones Brian
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

2.  Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.

Authors:  Guoxiong Xu; Miriam Barrios-Rodiles; Mirjana Jerkic; Andrei L Turinsky; Robert Nadon; Sonia Vera; Despina Voulgaraki; Jeffrey L Wrana; Mourad Toporsian; Michelle Letarte
Journal:  Mol Cell Proteomics       Date:  2013-12-07       Impact factor: 5.911

3.  Myoglobin overexpression inhibits reperfusion in the ischemic mouse hindlimb through impaired angiogenesis but not arteriogenesis.

Authors:  Joshua K Meisner; Ji Song; Brian H Annex; Richard J Price
Journal:  Am J Pathol       Date:  2013-10-01       Impact factor: 4.307

4.  Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.

Authors:  Shweta Joshi; Donald L Durden; Kevin X Liu; Muamera Zulcic; Alok R Singh; Dylan Skola; Christopher K Glass; P Dominick Sanders; Andrew B Sharabi; Timothy V Pham; Pablo Tamayo; Daniel Shiang; Huy Q Dinh; Catherine C Hedrick; Guillermo A Morales; Joseph R Garlich
Journal:  Mol Cancer Ther       Date:  2020-01-23       Impact factor: 6.261

5.  Chemokine-coupled β2 integrin-induced macrophage Rac2-Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis.

Authors:  Alan R Morrison; Timur O Yarovinsky; Bryan D Young; Filipa Moraes; Tyler D Ross; Nicolle Ceneri; Jiasheng Zhang; Zhen W Zhuang; Albert J Sinusas; Ruggero Pardi; Martin A Schwartz; Michael Simons; Jeffrey R Bender
Journal:  J Exp Med       Date:  2014-09-01       Impact factor: 14.307

6.  Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice.

Authors:  Gabor Szalai; Roberto Romero; Tinnakorn Chaiworapongsa; Yi Xu; Bing Wang; Hyunyoung Ahn; Zhonghui Xu; Po Jen Chiang; Birgitta Sundell; Rona Wang; Yang Jiang; Olesya Plazyo; Mary Olive; Adi L Tarca; Zhong Dong; Faisal Qureshi; Zoltan Papp; Sonia S Hassan; Edgar Hernandez-Andrade; Nandor Gabor Than
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

Review 7.  RAC1 Takes the Lead in Solid Tumors.

Authors:  Pradip De; Jennifer Carlson Aske; Nandini Dey
Journal:  Cells       Date:  2019-04-26       Impact factor: 6.600

8.  Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo.

Authors:  Shweta Joshi; Alok R Singh; Muamera Zulcic; Lei Bao; Karen Messer; Trey Ideker; Janusz Dutkowski; Donald L Durden
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

9.  Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype.

Authors:  Shweta Joshi; Alok R Singh; Simon S Wong; Muamera Zulcic; Min Jiang; Annie Pardo; Moises Selman; James S Hagood; Donald L Durden
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.752

10.  Bioinformatics analysis of microarray data to reveal the pathogenesis of brain ischemia.

Authors:  Jiaxuan He; Ya Gao; Gang Wu; Xiaoming Lei; Yong Zhang; Weikang Pan; Hui Yu
Journal:  Mol Med Rep       Date:  2018-05-09       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.